← 治験一覧に戻る
BeneFIX薬剤使用結果調査[全症例調査]
基本情報
- NCT ID
- NCT01154231
- ステータス
- 完了
- 試験のフェーズ
- -
- 試験タイプ
- 観察
- 目標被験者数
- 314
- 治験依頼者名
- Pfizer
概要
The survey is intended to investigate the following matters, etc. under the actual use status after marketing in all patients who are administered this drug for a certain period of time after the launch. 1. Occurrence status of adverse events 2. Factors that may influence the safety 3. Efficacy In addition, the following occurrence statuses will be investigated as priority items of the survey: Incidence rate of inhibitor, reduction in drug, efficacy, Allergic reaction, and Thrombosis.
対象疾患
Hemophilia B
介入
Nonacog Alfa (Genetical Recombination)(DRUG)
依頼者(Sponsor)
ファイザー株式会社(INDUSTRY)
実施施設 (1)
東京医科大学病院
Shinjuku-ku, Tokyo, Japan